These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15012692)

  • 1. Skeletal resistance to parathyroid hormone as a background abnormality in uremia.
    Fukagawa M; Iwasaki Y; Kazama JJ
    Nephrology (Carlton); 2003 Oct; 8 Suppl():S50-2. PubMed ID: 15012692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is aplastic osteodystrophy a disease of malnutrition?
    Fukagawa M; Akizawa T; Kurokawa K
    Curr Opin Nephrol Hypertens; 2000 Jul; 9(4):363-7. PubMed ID: 10926172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease.
    Massy Z; Drueke T
    J Nephrol; 2017 Oct; 30(5):629-634. PubMed ID: 28405928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Target range of PTH in uremia].
    Tahara H; Tabata T
    Clin Calcium; 2004 Jan; 14(1):39-44. PubMed ID: 15576952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adynamic bone disease: from bone to vessels in chronic kidney disease.
    Bover J; Ureña P; Brandenburg V; Goldsmith D; Ruiz C; DaSilva I; Bosch RJ
    Semin Nephrol; 2014 Nov; 34(6):626-40. PubMed ID: 25498381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical significance of adynamic bone disease in uremia.
    Fournier A; Said S; Ghazali A; Sechet A; Ezaitouni F; Marie A; Westeel PF; Morinière P; Boudailliez B
    Adv Nephrol Necker Hosp; 1997; 27():131-66. PubMed ID: 9408446
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Weekly Teriparatide on the Bone and Mineral Metabolism in Hemodialysis Patients With Relatively Low Serum Parathyroid Hormone: A Pilot Study.
    Yamamoto J; Nakazawa D; Nishio S; Ishikawa Y; Makita M; Kusunoki Y; Nagai S; Fujieda Y; Takahata M; Yamada K; Yamamura T; Yotsukura A; Saito M; Shimazaki M; Atsumi T
    Ther Apher Dial; 2020 Apr; 24(2):146-153. PubMed ID: 31210004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgically induced uremia in rats. II: Osseous PTH-susceptible signaling systems as predictors of bone resorption.
    Jablonski G; Danielsen CC; Mosekilde L; Gordeladze JO
    Calcif Tissue Int; 1994 Oct; 55(4):281-7. PubMed ID: 7820779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uremic Toxicity and Bone in CKD.
    Yamamoto S; Fukagawa M
    J Nephrol; 2017 Oct; 30(5):623-627. PubMed ID: 28573386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases.
    Fukagawa M; Kazama JJ; Shigematsu T
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S152-5. PubMed ID: 11576943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel mechanism for skeletal resistance in uremia.
    Slatopolsky E; Finch J; Clay P; Martin D; Sicard G; Singer G; Gao P; Cantor T; Dusso A
    Kidney Int; 2000 Aug; 58(2):753-61. PubMed ID: 10916099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PTH and bone metabolism in chronic dialysis patients].
    Fukagawa M; Kazama J; Shigematsu T
    Rinsho Byori; 2001 Mar; 49(3):236-8. PubMed ID: 11307321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new approach for evaluating bone turnover in chronic kidney disease.
    Tolouian R; Hernandez GT; Chiang WY; Gupta A
    Eur J Intern Med; 2010 Jun; 21(3):230-2. PubMed ID: 20493428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal osteodystrophy and secondary hyperparathyroidism.
    Fukagawa M; Kazama JJ; Kurokawa K
    Nephrol Dial Transplant; 2002; 17 Suppl 10():2-5. PubMed ID: 12386262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insufficiency of PTH action on bone in uremia.
    Iwasaki Y; Yamato H; Nii-Kono T; Fujieda A; Uchida M; Hosokawa A; Motojima M; Fukagawa M
    Kidney Int Suppl; 2006 Jul; (102):S34-6. PubMed ID: 16810309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [significance of PTH (1-84) assay in the management of chronic renal failure and the current status and future of the treatment of renal osteopathy].
    Akizawa T; Akiba T; Inaba M; Shigematsu T; Martin KJ
    Clin Calcium; 2005 Nov; 15(11):136-159. PubMed ID: 16315400
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of cytokines in renal osteodystrophy.
    Monier-Faugere MC; Malluche HH
    Curr Opin Nephrol Hypertens; 1997 Jul; 6(4):327-32. PubMed ID: 9263681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia.
    Quarles LD; Lobaugh B; Murphy G
    J Clin Endocrinol Metab; 1992 Jul; 75(1):145-50. PubMed ID: 1619003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.